Cargando…

Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves

Bronchoscopic lung volume reduction (BLVR) by endobronchial valve (EBV) implantation has been shown to improve dyspnea, pulmonary function, exercise capacity, and quality of life in highly selected patients with severe emphysema and hyperinflation. The most frequent adverse event is a pneumothorax (...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezel, Pascal, Wani, Jasmin, Wiederkehr, Gilles, Bodmer, Christa, Steinack, Carolin, Franzen, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780477/
https://www.ncbi.nlm.nih.gov/pubmed/35054134
http://dx.doi.org/10.3390/jcm11020440
_version_ 1784637848294522880
author Bezel, Pascal
Wani, Jasmin
Wiederkehr, Gilles
Bodmer, Christa
Steinack, Carolin
Franzen, Daniel P.
author_facet Bezel, Pascal
Wani, Jasmin
Wiederkehr, Gilles
Bodmer, Christa
Steinack, Carolin
Franzen, Daniel P.
author_sort Bezel, Pascal
collection PubMed
description Bronchoscopic lung volume reduction (BLVR) by endobronchial valve (EBV) implantation has been shown to improve dyspnea, pulmonary function, exercise capacity, and quality of life in highly selected patients with severe emphysema and hyperinflation. The most frequent adverse event is a pneumothorax (PTX), occurring in approximately one-fifth of the cases due to intrathoracic volume shifts. The majority of these incidents are observed within 48 h post-procedure. However, the delayed occurrence of PTX after hospital discharge is a matter of concern. There is currently no approved concept for its prevention. Particularly, it is unknown whether and when respiratory manoeuvers such as spirometry post EBV treatment are feasible and safe. As per standard operating procedure at the University Hospital Zurich, early spirometry is scheduled after BLVR and prior to the discharge of the patient in order to monitor treatment success. The aim of our retrospective study was to investigate the feasibility and safety of early spirometry. In addition, we hypothesized that early spirometry could be useful to identify patients at risk for late PTX, which may occur after hospital discharge. All patients who underwent BLVR using EBVs between January 2018 and January 2020 at our hospital were enrolled in this study. After excluding 16 patients diagnosed post-procedure with PTX and four patients for other reasons, early spirometry was performed in 61 cases. There was neither a clinically relevant PTX during or after early spirometry nor a late PTX following hospital discharge. In conclusion, we found early spirometry, conducted not sooner than three days following EBV treatment, to be feasible and safe. Furthermore, early spirometry seems to be a useful predictor for successful BLVR, and it may help to decide whether a patient can be discharged. Given the small sample size and the retrospective design of our study, a prospective study that includes routine chest imaging after early spirometry to definitively exclude PTX is needed to recommend early spirometry as part of the standard protocol following EBV treatment.
format Online
Article
Text
id pubmed-8780477
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87804772022-01-22 Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves Bezel, Pascal Wani, Jasmin Wiederkehr, Gilles Bodmer, Christa Steinack, Carolin Franzen, Daniel P. J Clin Med Article Bronchoscopic lung volume reduction (BLVR) by endobronchial valve (EBV) implantation has been shown to improve dyspnea, pulmonary function, exercise capacity, and quality of life in highly selected patients with severe emphysema and hyperinflation. The most frequent adverse event is a pneumothorax (PTX), occurring in approximately one-fifth of the cases due to intrathoracic volume shifts. The majority of these incidents are observed within 48 h post-procedure. However, the delayed occurrence of PTX after hospital discharge is a matter of concern. There is currently no approved concept for its prevention. Particularly, it is unknown whether and when respiratory manoeuvers such as spirometry post EBV treatment are feasible and safe. As per standard operating procedure at the University Hospital Zurich, early spirometry is scheduled after BLVR and prior to the discharge of the patient in order to monitor treatment success. The aim of our retrospective study was to investigate the feasibility and safety of early spirometry. In addition, we hypothesized that early spirometry could be useful to identify patients at risk for late PTX, which may occur after hospital discharge. All patients who underwent BLVR using EBVs between January 2018 and January 2020 at our hospital were enrolled in this study. After excluding 16 patients diagnosed post-procedure with PTX and four patients for other reasons, early spirometry was performed in 61 cases. There was neither a clinically relevant PTX during or after early spirometry nor a late PTX following hospital discharge. In conclusion, we found early spirometry, conducted not sooner than three days following EBV treatment, to be feasible and safe. Furthermore, early spirometry seems to be a useful predictor for successful BLVR, and it may help to decide whether a patient can be discharged. Given the small sample size and the retrospective design of our study, a prospective study that includes routine chest imaging after early spirometry to definitively exclude PTX is needed to recommend early spirometry as part of the standard protocol following EBV treatment. MDPI 2022-01-15 /pmc/articles/PMC8780477/ /pubmed/35054134 http://dx.doi.org/10.3390/jcm11020440 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bezel, Pascal
Wani, Jasmin
Wiederkehr, Gilles
Bodmer, Christa
Steinack, Carolin
Franzen, Daniel P.
Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title_full Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title_fullStr Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title_full_unstemmed Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title_short Early Spirometry Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves
title_sort early spirometry following bronchoscopic lung volume reduction with endobronchial valves
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780477/
https://www.ncbi.nlm.nih.gov/pubmed/35054134
http://dx.doi.org/10.3390/jcm11020440
work_keys_str_mv AT bezelpascal earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves
AT wanijasmin earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves
AT wiederkehrgilles earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves
AT bodmerchrista earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves
AT steinackcarolin earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves
AT franzendanielp earlyspirometryfollowingbronchoscopiclungvolumereductionwithendobronchialvalves